Silent killer: Tuberculosis claimed more lives than Covid-19 in Telangana
Officials figures published in a right-to-information response revealed that the number of people who died of TB in Telangana, India, was nearly double that of COVID-19 casualties in the same time period in 2020. TB claimed 2,784 lives in the State, while Covid-19 killed 1,544 people, the response stated.
TB works have taken a hit on the State-level too. Telangana wanted to eradicate TB from 10 districts, but the programme had to be postponed due to the pandemic. “TB is a bigger problem than Covid-19, but the number of deaths due to TB has not increased year after year. Last year, we saw nearly 80,000 cases in the State, for which the death rate was up to 4 per cent. However, the pandemic has had an adverse impact on TB prevention work as the staff had to be put on Covid-19 duty,” said Dr A Rajesham, joint director of State TB Cell.
Tuberculosis Testing Market to expand Rapidly in Asia Pacific through 2027
Transparency Market Research (TMR) has published a new report titled, ‘Tuberculosis Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global Tuberculosis Testing Market was valued at US$ 2,468.5 Mn in 2018 and is projected to expand at a CAGR of 4.0% from 2019 to 2027.
North America dominated the global Tuberculosis Testing Market in 2018 and the trend is anticipated to continue during the forecast period. Highly structured health care industry, and the Affordable Care Act in the U.S. are expected to drive the market in North America.
Asia Pacific is likely to be a highly lucrative market for tuberculosis and it is expected to expand at a high CAGR during the forecast period.
Birth Region Influences Time to TB Diagnosis among Immigrants in the United States
Approximately 90% of tuberculosis (TB) cases among non–US-born persons in the United States are attributable to progression of latent TB infection to TB disease. Using survival analysis, researchers investigated whether birthplace is associated with time to disease progression among non–US-born persons in whom TB disease developed. After adjusting for age at entry and birth year, the median time to TB diagnosis was lowest among persons from Middle Africa, 128 months for male persons and 121 months for female persons. The study showed that time to TB diagnosis among non–US-born persons varied by birth region, which represents a prognostic indicator for progression of latent TB infection to TB disease.